136 related articles for article (PubMed ID: 38402501)
21. Creatinine- versus cystatin C-based renal function assessment in the Northern Manhattan Study.
Husain SA; Willey JZ; Park Moon Y; Elkind MSV; Sacco RL; Wolf M; Cheung K; Wright CB; Mohan S
PLoS One; 2018; 13(11):e0206839. PubMed ID: 30427947
[TBL] [Abstract][Full Text] [Related]
22. A more accurate method acquirement by a comparison of the prediction equations for estimating glomerular filtration rate in Chinese patients with obstructive nephropathy.
Chen M; Xia J; Pei G; Zhang Y; Wu S; Qin Y; Deng Y; Guo S; Guo Y; Xu G; Han M
BMC Nephrol; 2016 Oct; 17(1):150. PubMed ID: 27756243
[TBL] [Abstract][Full Text] [Related]
23. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test.
Fan L; Inker LA; Rossert J; Froissart M; Rossing P; Mauer M; Levey AS
Nephrol Dial Transplant; 2014 Jun; 29(6):1195-203. PubMed ID: 24449101
[TBL] [Abstract][Full Text] [Related]
24. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
25. Creatinine Versus Cystatin C: Differing Estimates of Renal Function in Hospitalized Veterans Receiving Anticoagulants.
Wang CH; Rubinsky AD; Minichiello T; Shlipak MG; Price EL
J Gen Intern Med; 2018 Aug; 33(8):1299-1306. PubMed ID: 29855865
[TBL] [Abstract][Full Text] [Related]
26. Relationship between vascular function indexes, renal arteriolosclerosis, and renal clinical outcomes in chronic kidney disease.
Namikoshi T; Fujimoto S; Yorimitsu D; Ihoriya C; Fujimoto Y; Komai N; Sasaki T; Kashihara N
Nephrology (Carlton); 2015 Sep; 20(9):585-90. PubMed ID: 25854541
[TBL] [Abstract][Full Text] [Related]
27. Plasma neutrophil gelatinase-associated lipocalin as a potential predictor of adverse renal outcomes in immunoglobulin A nephropathy.
Park GY; Yu CH; Kim JS; Kang YJ; Kwon O; Choi JY; Cho JH; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2015 May; 30(3):345-53. PubMed ID: 25995665
[TBL] [Abstract][Full Text] [Related]
28. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
Inker LA; Heerspink HJL; Tighiouart H; Chaudhari J; Miao S; Diva U; Mercer A; Appel GB; Donadio JV; Floege J; Li PKT; Maes BD; Locatelli F; Praga M; Schena FP; Levey AS; Greene T
Am J Kidney Dis; 2021 Sep; 78(3):340-349.e1. PubMed ID: 33775708
[TBL] [Abstract][Full Text] [Related]
29. Effect of Pregnancy and Delivery on the Renal Function and the Prognosis of Patients with Chronic Kidney Disease Stage 3 Caused by Immunoglobulin A Nephropathy.
Shimizu A; Takei T; Moriyama T; Itabashi M; Uchida K; Nitta K
Intern Med; 2015; 54(24):3127-32. PubMed ID: 26666598
[TBL] [Abstract][Full Text] [Related]
30. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
31. Association of Intraindividual Difference in Estimated Glomerular Filtration Rate by Creatinine vs Cystatin C and End-stage Kidney Disease and Mortality.
Chen DC; Shlipak MG; Scherzer R; Bauer SR; Potok OA; Rifkin DE; Ix JH; Muiru AN; Hsu CY; Estrella MM
JAMA Netw Open; 2022 Feb; 5(2):e2148940. PubMed ID: 35175342
[TBL] [Abstract][Full Text] [Related]
32. The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Potok OA; Ix JH; Shlipak MG; Katz R; Hawfield AT; Rocco MV; Ambrosius WT; Cho ME; Pajewski NM; Rastogi A; Rifkin DE
Am J Kidney Dis; 2020 Dec; 76(6):765-774. PubMed ID: 32682697
[TBL] [Abstract][Full Text] [Related]
33. Utility of remission criteria for the renal prognosis of IgA nephropathy.
Matsuzaki K; Suzuki H; Kawamura T; Tomino Y; Suzuki Y
Clin Exp Nephrol; 2021 Sep; 25(9):988-995. PubMed ID: 33974158
[TBL] [Abstract][Full Text] [Related]
34. Home-based aerobic exercise and resistance training for severe chronic kidney disease: a randomized controlled trial.
Uchiyama K; Adachi K; Muraoka K; Nakayama T; Oshida T; Yasuda M; Hishikawa A; Minakuchi H; Miyashita K; Tokuyama H; Wakino S; Itoh H
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1789-1802. PubMed ID: 34554649
[TBL] [Abstract][Full Text] [Related]
35. Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients.
Hu Y; Shang M; Shi Y; Tao M; Yuan W; Tang L; Ma X; Cui B; Chen H; Zhou X; Zhuang S; Liu N
Ren Fail; 2021 Dec; 43(1):684-697. PubMed ID: 33896334
[TBL] [Abstract][Full Text] [Related]
36. Geriatric assessment of estimated glomerular filtration rate: a cross-sectional study.
Yamaguchi Y; Itabashi M; Yumura W; Takei T
Clin Exp Nephrol; 2020 Mar; 24(3):216-224. PubMed ID: 31617027
[TBL] [Abstract][Full Text] [Related]
37. Heart rate recovery after exercise is associated with renal function in patients with a homogenous chronic renal disease.
Késoi I; Sági B; Vas T; Kovács T; Wittmann I; Nagy J
Nephrol Dial Transplant; 2010 Feb; 25(2):509-13. PubMed ID: 19783602
[TBL] [Abstract][Full Text] [Related]
38. Cystatin C measurement leads to lower metformin dosage in elderly type 2 diabetic patients.
Šálek T; Adamíková A
Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):298-302. PubMed ID: 30218617
[TBL] [Abstract][Full Text] [Related]
39. Impact of body mass index on progression of primary immunoglobulin a nephropathy.
Nagaraju SP; Rangaswamy D; Mareddy AS; Prasad S; Kaza S; Shenoy S; Saraf K; Attur RP; Parthasarathy R; Kosuru S; Mateti UV; Guddattu V; Koulmane Laxminarayana SL
Saudi J Kidney Dis Transpl; 2018; 29(2):318-325. PubMed ID: 29657199
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH; Barratt J; Heerspink HJL; Alpers CE; Bieler S; Chae DW; Diva UA; Floege J; Gesualdo L; Inrig JK; Kohan DE; Komers R; Kooienga LA; Lafayette R; Maes B; Małecki R; Mercer A; Noronha IL; Oh SW; Peh CA; Praga M; Preciado P; Radhakrishnan J; Rheault MN; Rote WE; Tang SCW; Tesar V; Trachtman H; Trimarchi H; Tumlin JA; Wong MG; Perkovic V;
Lancet; 2023 Dec; 402(10417):2077-2090. PubMed ID: 37931634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
